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select lantibiotics (nisin, epidermin, mersacidin, and ac-
tagardine), ramoplanin captures Lipid I and II. Seques-
tration of Lipid I/II by ramoplanin precludes their normal
utilization as substrates by MurG and the transglycosy-
lase (TGase) enzymes. As a result, bacteria produce a
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goes a ligand-induced aggregation resulting in the for-Philadelphia, Pennsylvania 19104
mation of insoluble fibrils. Solublization of the fibrils with
20% dimethylsulfoxide (DMSO) facilitated determination
of dissociation constants and identification of the bind-Summary
ing interface with PG monomers by NMR [16]. It was
shown that the majority of chemical shift changes andThe peptide antibiotic ramoplanin is highly effective
intermolecular NOEs in the complex were localized be-against several drug-resistant gram-positive bacteria,
tween the muramyl carbohydrate and adjacent pyro-including vancomycin-resistant Enterococcus faecium
phosphate of the PG monomer and the Hpg3 -Orn10(VRE) and methicillin-resistant Staphylococcus aureus
stretch of ramoplanin (Figure 1). This octapeptide stretch(MRSA), two important opportunistic human patho-
is also conserved among the primary sequences of en-gens. Ramoplanin inhibits bacterial peptidoglycan
duracidins A and B [18–20] and likely is found in janie-(PG) biosynthesis by binding to Lipid intermediates I
mycin [21–23], cell-wall-active peptide antibiotics thatand II at a location different than the N-acyl-D-Ala-D-
are predicted to possess Lipid I/II binding activity [16].Ala dipeptide site targeted by vancomycin. Lipid I/II
Furthermore, ramoplanin’s overall fold is shared by twocapture physically occludes these substrates from
lantibiotics, mersacidin [24–27] and actagardine [28],proper utilization by the late-stage PG biosynthesis
strongly suggesting that all three antibiotics are func-enzymes MurG and the transglycosylases. Key struc-
tionally related [16, 28–32].tural features of ramoplanin responsible for antibiotic
In this report, we take steps toward reducing the com-activity and PG molecular recognition have been dis-
plex structure of ramoplanin to its minimalist bioactivecovered by antibiotic semisynthetic modification in
pharmacophore. Here, we dissect the contribution ofconjunction with NMR analyses. These results help
functional groups within the ramoplanin sequence anddefine a minimalist ramoplanin pharmacophore and
assess their effects on its antimicrobial activity, its abilityintroduce the possibility of generating ramoplanin-
to bind bacterial PG biosynthesis monomers and relatedderived peptide or peptidomimetic antibiotics for use
synthetic analogs (Figure 2), and to form fibrils via self-against VRE, MRSA, and related pathogens.
association of the antibiotic-PG monomer complex. De-
fining the minimal structural requirements responsible
Introduction for ramoplanin’s antimicrobial activity will help facilitate
chemical synthesis of the antibiotic by reducing struc-
The widespread use of broad-spectrum antibiotics has tural complexity and will also promote judicious chemi-
placed enormous selective pressures on bacterial popu- cal modification for structure/activity analyses and mod-
lations, forcing the evolution of resistance mechanisms ulation of biological or physiochemical properties. The
[1, 2]. Antibiotic resistance results in morbidity and mor- information gained from these studies will help guide the
tality from treatment failures and increased health care design of ramoplanin-derived anti-VRE or anti-MRSA
costs [3]. The lipoglycodepsipeptide antibiotic ramo- antibiotics.
planin factor A2 (1, Figure 1) is a promising candidate
for treatment of antibiotic-resistant gram-positive infec-
tions. Produced by Actinoplanes ATCC 33076, ramo- Results and Discussion
planin is highly active against numerous gram-positive
bacteria, including MRSA [4–8], VRE, and those resistant Ramoplanin and Enduracidin Are Structurally
to ampicillin and erythromycin [8–13]. It is currently in and Functionally Related
phase III clinical trials in the United States for the sup- Previously, we used NMR methods combined with
pression of VRE in the gastrointestinal tract and for pre- chemical synthesis to isolate the minimal region of PG
vention of bloodstream infections caused by VRE. To capable of associating with ramoplanin and to deter-
date, no cases of clinical or laboratory-generated resis- mine the structure of the ramoplanin-PG intermediate
tance to the antibiotic have been reported [14, 15]. binding interface [16]. It was determined that residues
Ramoplanin does not target an enzyme directly, but Hpg3 -Orn10 of ramoplanin participated in binding PG bio-
rather sequesters the substrates of PG biosynthesis en- synthetic intermediates (Figure 1). In this study, we turn
zymes. In a similar manner as the glycopeptides and our attention to investigating the structural basis for
ramoplanin’s biological activity in hopes of defining a
minimal bioactive pharmacophore and to further dissect3 Correspondence: deweym@mail.med.upenn.edu
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Figure 1. Chemical Structures of the Antibiotic Ramoplanin Factor A2 from Actinoplanes ATCC 33076, the Semisynthetic Ramoplanin Analogs
Prepared in This Study, and the Structurally Related Enduracidin Antibiotics from Streptomyces fungicidicus B5477
Common structural elements of the sequences of ramoplanin and enduracidins are colored blue. Divergent structural elements are colored
red. Highlighted in yellow are the amino acid residues that exhibit marked NMR chemical shift changes upon binding PG precursors [16]. A
similar sequence is found in the enduracidins. Nonstandard residues are denoted as follows: Chp, 3-chloro-4-hydroxyphenylglycine; Cit,
citrulline; Dpg, 3,5-dichloro-4-hydroxyphenylglycine; End, enduracididine; Hpg, 4-hydroxyphenylglycine.
the sequence requirements responsible for high affinity duracididine (End10) and citrulline (Cit9) are found in posi-
tions corresponding to the Orn10 and Phe9 residues ofPG biosynthetic intermediate recognition and antibiotic
activity. ramoplanin. The similarity of the PG recognition se-
quences of the two antibiotics strongly suggests thatA substructure search of the Hpg3 -Orn10 sequence
in known peptide antibiotics yielded the enduracidin they possess similar mechanisms of action.
To test this hypothesis, we examined enduracidin forfamily of cell-wall-active lipodepsipeptide antibiotics
produced by Streptomyces fungicidicus B5477 [19]. its ability to bind to citronellyl-Lipid I (10), a soluble
derivative of the PG biosynthesis intermediate Lipid IHighly homologous to ramoplanin, the enduracidins
contain the sequence allo-Thr8 -D-Hpg7 -Hpg6 -D-allo- [33], and to self-associate following complexation. Since
similar behavior has been observed for ramoplanin withThr5 -D-Orn4 -D-Hpg3 , which exhibits sequence similarity
to ramoplanin’s Hpg3 -Orn10 PG recognition sequence compound 10, aggregate formation (e.g., fibril formation
for ramoplanin) serves as a convenient predictor of PG(Figure 1) [18]. In the enduracidins, the amino acids en-
complexation [16]. Indeed, upon mixing equimolar ho-
mogeneous solutions of enduracidin (1 mM, 4% DMSO)
with 10 (1 mM), an amorphous precipitate formed imme-
diately (Figure 3). MS analysis of the precipitate showed
that it contained both enduracidin and 10. Similar aggre-
gates were obtained by mixing enduracidin solutions
Figure 2. Chemical Structures of Synthetic and Naturally Occurring Figure 3. Transmission Electron Micrograph of the Aggregate Formed
from the Complexation of Enduracidin with Compound 10Analogs of Bacterial Peptidoglycan Monomers Used in This Study
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with solutions of compounds 11 or 12. Due to the low an important structural component. These observations
are also consistent with possible participation of resi-solubility of enduracidin in aqueous solutions, DMSO
was added to facilitate its dissolution; thus a final con- dues upstream of Hpg3 (e.g., Asn1, Asn2 , or Chp17) in
binding Lipid I/II or stabilizing the bioactive conforma-centration of 2% DMSO was present in the complexation
assay. We have previously shown that addition of DMSO tion and, taken together with the functional parallels
between ramopanin and enduracidin, strongly suggestreduces or altogether eliminates fibril formation during
complexation of ramoplanin with compounds 11 or 12 the existence of a common bioactive pharmacophore.
[16]. Since an amorphous aggregate formed instead of
an ordered fibril as was observed for ramoplanin, it is
Glycosylation Confers Both Conformationallikely that the presence of 2% DMSO required to so-
Stability and Protection from Acidlublize enduracidin was of sufficient concentration to
Hydrolysis to Ramoplanincompete for intercomplex hydrogen bonding and/or-
We wished to establish whether the mannose disaccha-interactions that might have been critical for the forma-
ride group at position Hpg11 influenced Lipid I/II binding.tion and coalescence of protofibrils or aggregates into
Ciabatti and coworkers demonstrated that this carbohy-ordered fibrils. The limited solubility of enduracidin in
drate could be hydrolyzed by treatment with trimethylsi-water might also play a role in altering the morphology
lyl iodide [38, 39]. The resulting aglycon possesses anti-of the precipitate. Nevertheless, these observations are
microbial activity comparable to the parent antibiotic,strongly suggestive of the existence of a common mech-
suggesting that this structural element is not essentialanism of action for both ramoplanin and enduracidin.
for antimicrobial activity [38, 39]. The enduracidins are
not glycosylated, yet both ramoplanin and enduracidin
similarly bind PG biosynthesis monomers in vitro andStructural Comparison of Enduracidin to Ramoplanin
Suggests the Existence of a Common exhibit potent antimicrobial activity in vivo. We prepared
ramoplanin aglycon (2), purified it to homogeneity byAntibiotic Pharmacophore
Enduracidin and ramoplanin share a number of struc- HPLC, and confirmed Ciabatti’s observation of equiva-
lent antimicrobial activity as the parent antibiotic againsttural similarities that point to a common bioactive antibi-
otic pharmacophore (Figure 1). Both are 17-residue lipo- a B. subtilis gram-positive bacterial test strain (MIC 
0.03 g/ml for both antibiotics) [38, 39]. As predicted,depsipeptides. Both are N-acylated with cis,trans fatty
acids, although the acyl chains in enduracidins A and titration of a solution of 2 (1.0 mM) against PG monomer
analogs citronellyl-Lipid I (10) [33, 40], Park’s nucleotideB are considerably longer than that of ramoplanin factor
A2, and correspondingly these antibiotics are less solu- (11) [41], and UDP-MurNAc-tripeptide (12) resulted in
the formation of insoluble fibrils (Figure 4). As depictedble than ramoplanin in water. However, unsaturation
of this acyl appendage appears to be unimportant, for in Table 1, 1H NMR titration experiments conducted in
DMSO/D2O (20:80, v/v), a solvent mixture capable ofCiabatti and coworkers previously showed that catalytic
hydrogenation of ramoplanin to afford the fully saturated greatly minimizing fibril formation, facilitated the deter-
mination of dissociation constants (Kd) for the antibiotic-N-acyl tail did not alter its antibiotic activity [34].
Both antibiotics appear to require chlorinated hy- ligand complex. The complex was in fast exchange with
its dissociated components on the NMR chemical shiftdroxyphenylglycine residues. In ramoplanin, a monochl-
orinated hydroxyphenylglycine is found in position 17. timescale [16]. The combination of residual fibril forma-
tion and NMR spectral overlap between the citronellylThis residue is one of the three aryl groups comprising
the Chp17-Hpg3 -Phe9 hydrophobic core. In the NMR methyls and lactyl ether methyls of 10 limits the accuracy
of the determined Kd to a simple upper boundary esti-structure of ramoplanin [35], the chlorine of Chp17 ap-
pears to serve a stabilizing role, as it is buried deep mate of 200 M. Similar measurements indicate that
aglycon 2 has a2-fold lower affinity for Park’s nucleo-within this hydrophobic core. Similarly, enduracidins
contain a dichlorinated hydroxyphenylglycine in posi- tide 11 (Kd  330  30 M) when compared to ra-
moplanin (Kd  180  20 M), but an almost 2-foldtion 13 (Dpg13) (Figure 1). Ramoplanin residue 13 lies
juxtaposed across the  sheet from Chp17, so it is possi- increased affinity for compound 12 (Kd  1300  30 M
versus Kd  2380 30 M). Glycosylation of ramoplaninble that Dpg13 might function in a similar manner as Chp17
to stabilize the conformation of enduracidins. Similar therefore imparts no influence on antimicrobial activity
and only has a slight influence on the energetics of PGchlorinated aryl groups are found in complestatin, the
chloropeptins, kistamycin, and the glycopeptide antibi- monomer binding.
Removal of the disaccharide both increased confor-otic vancomycin. In the case of the latter, removal of
the chlorines alters its antimicrobial activity [36, 37]. It mational flexibility and susceptibility of the aglycon to
acid hydrolysis. Comparison of the 2D NMR NOESYremains to be determined if chlorination is important for
the antimicrobial activity of ramoplanin or the endura- spectra of ramoplanin with aglycon 2 showed that the
aglycon exists in multiple conformations in solution, butcidins.
Ramoplanin contains a lactone formed between the the parent compound 1 exists in a single conformation
on the NMR timescale (data not shown). Since glycosyla--carboxylate of Chp17 and the 3-hydroxyl of-OH-Asn2 .
The enduracidins contain a structurally less complex tion can confer conformational stability to proteins and
peptides [42], it is believed that ramoplanin’s mannosyllactone linkage between the -carboxylate of Hpg17 and
the side chain hydroxyl of Thr2 (Figure 1). As will be disaccharide helps stabilize the  sheet conformation.
During preparative purification of aglycon 2 by HPLC,detailed below, the significantly reduced antibiotic activ-
ity of linearized ramoplanin suggests that the lactone is we observed the time-dependent decomposition of the
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Figure 4. NMR Analysis of Peptidoglycan Biosynthesis Intermediate Complexation by Ramoplanin Aglycon (2)
(A) Part of the aliphatic region of the 1H NMR spectrum of free ramoplanin aglycon (2), free Park’s nucleotide (11), and a 1:1 mixture of the
two illustrating the chemical shift changes that occur upon binding.
(B) Representative transmision electron micrograph of the fibrils formed from the complexation of aglycon 2 with Park’s nucleotide (11). Fibrils
formed from the interaction of ramoplanin (1) or its derivatives 2–4 with citronellyl-Lipid I (10) and Park’s nucleotide (11), respectively, exhibited
similar morphology.
(C) Representative Kd determination plot of the binding of ramoplanin aglycon (2) to Park’s nucleotide (11) as obtained by 1H NMR titration.
The curve denotes the experimental (open circles) and calculated (solid line) chemical shifts () of the lactyl ether methyl protons (3a) of 11
as a function of ramoplanin concentration.
antibiotic in acidic solutions. Although decomposition [43]. Glycosylation therefore likely occurs after nonribo-
somal peptide assembly by glycosyltransferases in-is rapid in neat trifluoroactic acid, modest rates of de-
composition occurred in 0.1% aqueous TFA and during volved with other primary or secondary metabolism pro-
cesses. Although the biosynthetic locus for enduracidinexposure to solutions containing 1%–10% HCl or AcOH.
In contrast, the parent antibiotic was completely resis- has not yet been identified and sequenced, Streptomy-
ces fungicidicus B5477 apparently has not evolved ortant to acid hydrolysis over the same time regimes and
conditions examined. It is likely that ramoplanin glyco- does not employ glycosylation as a protective measure,
perhaps because the antibiotic is perfectly stable in thesylation reflects an evolutionary adaptation by its Acti-
noplanes producer for ensuring antibiotic integrity in environment to which it is released or because primary
structural differences between ramoplanin and endura-low-pH extracellular environments, for antibiotic protec-
tion from deleterious proteolytic degradation, or for pro- cidin are sufficient to confer peptide stability. Endura-
cidin, like ramoplanin, is known to be highly stable inducer immunity. Collectively, these studies confirm that
dimannosylation of Hpg11 does not influence ramopla- acidic solutions [44].
Since aglycon 2 contains the full complement of wild-nin’s antibiotic activity but likely serves to protect the
antibiotic from deleterious hydrolysis. type ramoplanin’s antimicrobial activity, removal of the
mannosyl disaccharide from 1 leads to a bioactive phar-Intriguingly, unlike glycopeptide and macrolide antibi-
otics, specific genes encoding glycosyltransferases are macophore with significantly reduced chemical com-
plexity. Boger and coworkers have recently describednot found within the ramoplanin biosynthetic gene locus
Table 1. Fibril Formation and Dissociation Constants of Ramoplanin and Related Analogs with Peptidoglycan Precursors and Related
Fragments
Ramoplanin Analogs
1 2 3 4 5 6
Peptidoglycan
Fibril Formation (Yes/No, Conditions), Dissociation Constant (M)Analogs
10 Y(A), Y(B) Y(A), Y(B) N(A), N(B) N(A), N(B) N(A), N(B) N(A), N(B)
p.p. p.p. n.d. n.d. n.d. n.i.
11 Y(A), N(B) Y(A), N(B) Y(A), N(B) Y(A), N(B) Y(A), N(B) N(A), N(B)
180  20 330  50 170  30 130  20 1340  320 n.i.
12 Y(A), N(B) Y(A), N(B) Y(A), Y(B) Y(A), N(B) Y(A), N(B) N(A), N(B)
2380  440 1300  230 n.d. 1280  140 n.i. n.i.
Conditions for complexation and fibril formation: [ramoplanins]  1.0 mM, [peptidoglycan fragments/analogs]  1.0 mM in either (A) D2O (pH
7.0) or (B) 20% DMSO/D2O (pH 7.0). Dissociation constants were determined by 1H NMR titration at 600 MHz in 20% DMSO-d6/D2O (pH 7.0).
n.i., no appreciable interaction, i.e., a homogeneous solution with no antibiotic-peptidoglycan precursor binding was observed or Kd 	 10
mM as determined by 1H NMR; p.p., partial precipitation precluded accurate Kd determination; n.d., not determined. Peptidoglycan fragments
13–15 failed to associate with derivatives 1–6 under these conditions.
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Figure 5. Interaction of [Orn4,Orn10]-Diguanidylated Ramoplanin with Park’s Nucleotide
(A) Aromatic and amide region of the 1H NMR spectrum of free [Orn4 ,Orn10]-diguanidylated ramoplanin (3). The spectrum was obtained at 500
MHz at 25
C in D2O (pH 6.0).
(B) The same aromatic and amide region of the 1H NMR spectrum of [Orn4 ,Orn10]-diguanidylated ramoplanin (3) with equimolar Park’s nucleotide
(11) depicting the line broadening and chemical shift changes that occur upon binding.
(C) Isothermal titration calorimetry data from the titration of [Orn4 ,Orn10]-diguanidylated ramoplanin (3) with compound 11. The complex pattern
of heat released during the titration is indicative of ligand-induced aggregation [46, 47].
an elegant total synthesis of the aglycon of ramoplanin or aglycon 2. In 20% DMSO, the Kd of ramoplanin deriva-
tive 3 with PG precursor 11 was nearly identical to thatA2 and ramoplanose by solution-phase methods [45].
Avoidance of construction of ramoplanin’s dimannosyl of wild-type 1 (170  30 M); however, soluble fibril
formation during the NMR titration precluded Kd deter-carbohydrate will certainly facilitate the chemical as-
sembly of analogs for structure/activity studies. mination with 12 (Table 1).
[Orn4 ,Orn10]-Diisovaleryl ramoplanin (4), prepared by re-
ductive alkylation with isovaleryl aldehyde and NaCNBH3,Ramoplanin Ornithines 4 and 10 Participate in Capture
of Peptidoglycan Lipid Intermediates maintains the side chain amine cationic charge but con-
tains increased steric bulk about the ornithine sidechainPreviously, we determined that ramoplanin residues Hpg3 -
Orn10 are involved in the capture of PG intermediates amine. This compound shows a significantly reduced MIC
(4 g/ml; 133-fold lower than wild-type), yet the dissocia-[16]. Ornithines 4 and 10 are the only charged residues
in the ramoplanin sequence and thus are candidates for tion constants of 4 with compounds 11 and 12 were
slightly lower than wild-type (130  20 M and 1280 interacting with the anionic Lipid I/II pyrophosphate and/
or peptidyl carboxylates. To examine the contribution 140 M, respectively) (Table 1).
Finally, removal of the cationic charge by [Orn4 , Orn10]-of individual ramoplanin functional groups in the recog-
nition of PG monomers, several semisynthetic modifica- diacetylation produced derivative 5. This compound ex-
hibited both a markedly reduced antibiotic activitytions were performed on the antibiotic, and their antimi-
crobial and PG binding properties were assessed. Orn (MIC  16 g/ml; 533-fold lower than ramoplanin) and
almost a 10-fold decrease in binding affinity with 11residues were converted to guanidine, secondary amine,
and acetamide functional groups, purified, and as- (Kd  1340  320 M) (Table 1). Furthermore, it failed
to show detectable binding to 12. The strong correlationsessed for antimicrobial activity and for the ability to
bind to PG intermediates and/or to form fibrils (Table 1). between the presence of cationic charges on the Orn4 ,
Orn10 -amino groups and the affinity of the antibioticTreatment of ramoplanin (1) with 1H-pyrazole-1-car-
boxamidine provided the [Orn4 ,Orn10]-diguanidylated toward PG precursors 11 and 12 support the hypothesis
that these residues anchor the PG ligand in the properderivative 3 that possessed a MIC of 0.25 g/ml, a value
approximately 8-fold higher than the wild-type antibi- orientation for binding using electrostatic or hydrogen
bonding interactions [16]. Preservation of charge onotic. NMR analysis of ramoplanin derivative 3 with PG
precursors 11 or 12 in D2O showed clear evidence of these residues is also essential for antimicrobial activity,
with the general order of activity of 1
amine	guanidine	complexation and formation of a large, soluble aggre-
gate (Figure 5). Results from isothermal titration calorim- 2
 amine for those analogs tested.
Although enduracidins contain only one ornithineetry experiments conducted with 3 and 11 also clearly
indicated that a ligand-induced aggregation occurred (Orn4 ), they do, however, contain two cationic guani-
dine-like enduracididine residues in position 10 (End10)during the titration (Figure 5) [46, 47]. Insoluble fibrils
could be produced from soluble fibril preparations by and in position 15 (End15) (Figure 1). It is likely that End10
functions in a similar manner as Orn10 of ramoplanin.increasing the ionic strength to100 mM. Fibrils formed
under these high ionic strength conditions exhibited These results suggest that ramoplanin positions 4 and/
or 10 are able to tolerate a number of diverse substitu-similar morphology to those formed by ramoplanin (1)
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tions, providing they maintain a positive charge at these (Figure 6). The NMR chemical shift data indicated that
peptide 16 binds to the terminal D-Ala-D-Ala dipeptidesites.
of 11 under these concentrations. Ramoplanin binds
primarily to the muramyl carbohydrate and adjacent
Ramoplanin Employs a Conformationally L-Ala residue of PG precursors, but significant contacts
Constrained Recognition Sequence are made to the pentapeptide terminus. In fact, deletion
for Capture of Lipid Intermediates of the last two D-Ala residues reduces binding affinity
To determine if the Hpg3 -Orn10 ramoplanin sequence on average by 10-fold [16]. In this conformationally con-
and flanking residues were capable of sequestering strained peptide, we have dissected out a subset of
peptidogycan derivatives when presented in the form ramoplanin’s binding interface with 11. Although the
of a linear peptide instead of the wild-type conformation- observed interaction is clearly distinct and specific for
ally constrained lactone, we converted ramoplanin (1) the pentapeptide terminus of 11, peptide 16 was devoid
into its linear form (6) by hydrolysis with 1% triethyla- of antimicrobial activity to 	512 g/ml, suggesting that
mine/water [48] and tested its ability to bind PG analogs antimicrobial activity requires additional residues or is
by NMR. Williams and coworkers previously demon- supported by an alternate receptor conformation which
strated that the hydrolyzed linear form of the closely might have been disallowed by the design of 16.
related antibiotic ramoplanose maintained significant Although ramoplanin derivative 16 bound Park’s nu-
native-like  sheet structure in D2O after hydrolysis [48]. cleotide with modest affinity, it neither possessed anti-
We found that linearized ramoplanin possessed a MIC microbial activity nor formed fibrils following ligand cap-
value of 64 g/ml, a 2133-fold increase from that of the ture. This interesting observation raises the question as
wild-type antibiotic (0.03 g/ml). Thus, almost all of the to what, if any, physiological role antibiotic oligomeriza-
antibiotic activity was lost when the lactone was hy- tion or intermolecular complex association (i.e., fibril
drolyzed. Compound 6 did not bind citronellyl-Lipid I formation) might play in the bacterial killing mechanism.
(10) nor related compounds 9 or 11–15 (Table 1). This Previously, we provided evidence of a ligand-induced
data suggests that high-affinity capture of PG monomers conformational change in ramoplanin that results in the
requires presentation of residues along the Hpg3 -Orn10 flattening of its cup-shaped architecture when liganded
sequence in a specific three-dimensional conformation. [16]. Following complexation, the Chp17-Hpg3 -Phe9 hy-
Presentation in its bioactive conformation is facilitated drophobic core becomes exposed to bulk solvent, cre-
by the constraining Asn2 -Chp17 lactone. These data also ating a potential surface for intermolecular aggregation
suggest that important interactions not previously iden- [16]. It has not yet been established if ramoplanin-PG
tified by NMR analysis in 20% DMSO are present only Lipid intermediate complexes polymerize in a mem-
when the lactone is intact. brane environment as they do in free solution. Once
To confirm that residues along the Hpg3 -Orn10 stretch liganded, the conformational changes observed by ra-
of ramoplanin were necessary and sufficient for PG com- moplanin in solution and concomitant intercomplex ag-
plexation, we designed and synthesized the cyclic pep- gregation certainly raise the possibility that oligomeriza-
tide N-octanoyl-Asn-Asn-cyclo[Cys-D-Orn-Phe-alloThr- tion could occur at the level of the membrane, where it
D-Hpg-D-alloThr-Hpg-Cys]-D-Orn-NH2 (16, Figure 6), a would be expected to impart beneficial effects, such as
conformationally constrained mimic of the Hpg3 -Orn10 improved capture of both PG monomers and actively
ramoplanin PG recognition sequence, and examined its polymerizing PG chains.
propensity to bind Park’s nucleotide (11) by NMR. Pep-
tide 16 was synthesized by standard Fmoc solid-phase
peptide synthesis methods and cyclized to the disulfide Conclusion: Toward a Minimalist Ramoplanin
In this study, we take steps toward further elucidatingby air oxidation in 20% DMSO (pH 8.0). Two cysteine
residues were placed in the sequence as replacements the molecular basis of ramoplanin’s complex mecha-
nism of action and defining a minimal bioactive pharma-for Hpg3 and Phe9 in order to constrain the peptide into
conformational subpopulations that orient Asn2 near cophore. These structure/activity experiments, taken to-
gether with comparative analysis of the structure andThr8 , as is observed in the NMR structure of ramoplanin
(Figure 6) [35]. In addition, ramoplanin’s N-acyl cis,trans function of ramoplanin and the enduracidins, imply that
a minimal functional pharmacophore exists that unites7-methyl-2,4-octadieneoic fatty acid was replaced by a
commercially available isosteric octanoic acid. the two antibiotic classes. Ciabatti and coworkers pre-
viously established that both glycosylation and N-acylTo determine if peptide 16 was capable of binding PG
monomers, we conducted an NMR titration of reduced lipid unsaturation were not required for conferring high-
level antimicrobial activity [34, 39]. Our structure/func-and oxidized 16 (0.5 mM) with Park’s nucleotide in D2O
(pH 6) (Figure 6). Dithiothreitol-reduced 16 did not inter- tion studies with ramoplanin highlight the significance of
Hpg11 mannosylation in instilling conformational stabilityact with compound 11. However, we did observe a spe-
cific interaction with the oxidized form of 16 and 11. The and resistance to degradation, the consequence of dis-
rupting the Chp17-Asn2 lactone bond on antimicrobialNMR spectrum of disulfide-linked 16 with 11 revealed
marked chemical shift changes indicative of complex- activity, the requirement for cationic charge on ramopla-
nin’s two ornithines, and the importance of presentation ofation, although no fibrils formed by visual inspection or
by electron microscopy analysis (Figure 6). The magni- the Hpg3 -Orn10 PG binding sequence in a conformationally
restrained manner. Since similar structural features aretude of these chemical shift changes resembled those
observed for ramoplanin with 11; however, due to the echoed by the enduracidins, one can assume that many
of these sequence and structural elements may be func-cooperative behavior of the complexation, a true Kd
value was not assigned but is estimated to be 1 mM tionally interchangeable between the two antibiotic
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Figure 6. Design and Biophysical Analysis of a Ramoplanin-Derived Cyclic Peptide that Binds a Peptidoglycan Biosynthesis Intermediate
(A) Surface representation of ramoplanin (1) based on the NMR solution structure obtained in 20% DMSO [35]. Residues participating in
capture of peptidoglycan monomer/lipid intermediates identified by NMR analysis are colored in yellow and lie on one face of the antibiotic
surface.
(B) Stick representation of the structure of ramoplanin showing that the residues comprising the binding interface lie along one of the two 
strands eminating from the Thr8 -Phe9 type I  turn.
(C) Covalent structure of a disulfide-linked conformationally constrained peptide designed to mimic structural and functional elements of
ramoplanin’s peptidoglycan intermediate capture motif.
(D) Part of the aliphatic region of the 1H NMR spectrum of free peptide 16 (cyclic disulfide form, bottom trace), free Park’s nucleotide (11, top
trace), and a 1:1 mixture of the two (middle trace) depicting the chemical shift changes that occur upon binding.
(E) Plot of binding of peptide 16 to Park’s nucleotide (11) as obtained by 1H NMR titration. The solid circles denote the chemical shifts () of
the lactyl ether methyl protons (3a) of 11 as a function of the concentration of 16.
types, potentially ameliorating chemical synthesis of the Significance
antibiotic and related analogs. Future structure/activity
studies will help ascertain the requirements for both Ramoplanin is an emerging clinical candidate antibi-
otic for treatment of VRE and MRSA infections. Thepeptidoglycan capture and antimicrobial activity and will
also shed light onto the interplay of intercomplex associ- antibiotic is in phase III trials for oral treatment of
enterococcal infections. Ramoplanin is significantlyation/fibril formation with antibiotic activity.
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[Orn4, Orn10]-Diisovaleryl Ramoplanin (4)more potent than vancomycin for treatment of gram-
A dry nitrogen-flushed 50 ml round bottom flask was charged withpositive bacterial infections. Here, we have further de-
Ramoplanin (200 mg, 0.0783 mmol, 1.0 eq), a teflon stirbar, andfined the essential structural elements of ramoplanin
sealed. Isovaleraldehyde (12 mg, 0.140 mmol, 1.8 eq, 15 l) in DMF
that confer antibiotic activity and high-affinity Lipid I/II (2 ml) was added by syringe and the solution was allowed to stir
binding. These results are significant because they for 2 hr. The solution was then treated with sodium cyanoborohy-
dride (15 mg, 0.234 mmol, 3.0 eq) and stirred for an additional 2.5suggest the existence of a minimalist pharmacophore
hr. The reaction was then quenched with 0.1% aqueous TFA (25and introduce the possibility of generating ramoplanin-
ml), purified by preparative reversed phase HPLC, and lyophilizedderived peptide or peptidomimetic antibiotics for use
to give 4 as a white solid (31.0 mg, 15%). MALDI TOF-MS calcd.against VRE, MRSA, and related pathogens.
2694.33, actual 2696.0 (MH); preparative HPLC conditions, Vydac
C18 column (25 mm  250 mm), mobile phase A  H2O/ACN/TFA
(80/20/0.1, v/v), mobile phase B  H2O/ACN/TFA (20/80/0.1, v/v);Experimental Procedures
analytical HPLC: Vydac C18 (4.5mm  250mm) Rt: 38.98 min.
Methods and Materials
Mass spectra were recorded on Perspective BioSystems Voyager-
[Orn4, Orn10]-Diacetylated Ramoplanin (5)DE RP MALDI-TOF or Hewlett-Packard ESI-MS spectrometers.
A dry nitrogen-flushed 50 ml round bottom flask was charged withTransmission electron micrographs were performed as previously
Ramoplanin (100 mg, 0.0392 mmol, 1.0 eq), a teflon stirbar, anddescribed [16]. HPLC was performed on a Thermo-Separations TSP
sealed. Acetonitrile (6 ml) and DMF (5.5 ml) were added by syringe,3000 system using Phenomenex Jupiter or Vydac octadecyl silica
and the stirred solution was chilled on an ice bath. Acetic anhydridecolumns. Fmoc-amino acids were purchased from Bachem. Routine
(8 mg, 0.0783 mmol, 2.0 eq) and a catalytic amount of pyridine (0.1one- and two-dimensional NMR spectroscopy was performed as
mol %) were added, the solution was stirred at 0
C for 1 hr and thenpreviously described [16]. Measurement of dissociation constants
allowed to warm to room temperature and stir for 3 hr. The solutionwas performed by NMR as previously reported [16]. Enduracidin
was then diluted with aqueous TFA (10 ml, 0.1% v/v) and purifiedwas purchased from Sigma. Deuterated solvents were purchased
by HPLC to afford 5 as a white solid (11.4 mg, 11%): MALDI TOF-MSfrom Aldrich and Cambridge Isotopes. UDP-MurNAc-L-Ala--D-Glu-
calcd. 2638.14, actual 2639.3 (MH); preparative HPLC conditions,meso-Dap-D-Ala-D-Ala (11, Park’s nucleotide), and UDP-MurNAc-
Vydac C18 column (25 mm  250 mm), mobile phase A  H2O/ACN/L-Ala--D-Glu-meso-Dap (12, UDP-MurNAc-tripeptide) were iso-
TFA (80/20/0.1, v/v), mobile phase B  H2O/ACN/TFA (20/80/0.1,lated from Bacillus subtilis ATCC 8037 according to the procedure
v/v); analytical HPLC, Vydac C18 (4.5 mm  250 mm) Rt: 36.09 min.of Holtje and coworkers [49]. 1-Phospho-MurNAc-L-Ala--D-Glu-
meso-Dap (13) was prepared according to the Van Heijenoort
method [50]. L-Ala--D-Glu-D-Lys-D-Ala-D-Ala (9) and MurNAc-L- N-Octanoyl-Asn-Asn-cyclo[Cys-D-Orn-Phe-alloThr-D-
Ala--D-Gln (15) were purchased from Bachem. P1-Citronellyl-P2 - Hpg-D-alloThr-Hpg-Cys]-D-Orn-NH2 (16)
MurNAc-L-Ala--D-Glu-L-Lys-D-Ala-D-Ala pyrophosphate (10) and The linear peptide was prepared by solid-phase peptide synthesis
the related MurNAc pyrophosphate 14 were prepared as previously on an Applied Biosystems 433 peptide synthesizer on a 0.25 mmol
described [40]. Ramoplanin A2 aglycon (2) was synthesized by the scale using Fmoc-protected amino acids and HBTU/HOBt activa-
method of Ciabatti [39]. Linearized Ramoplanin A2 (6) was produced tion. No side chain protection was employed for allo-Thr and Hpg
by the procedure of Williams [48]. Minimal inhibitory concentrations residues. Following assembly of the linear peptide sequence, the N
were performed as previously reported [16]. terminus was acylated with octanoic acid (Acros Chemicals). The
peptide resin was cleaved with TFA/H2O/EDT (94:2.5:2.5:1 v/v) for
3 hr at room temperature according to standard methods, and theIsothermal Titration Calorimetry
crude peptide was precipitated with cold Et2O (40
C). Intramolecu-Isothermal titration calorimetry (ITC) experiments to measure inter-
lar cyclization to the disulfide was accomplished by stirring a ca. 1action of Park’s nucleotide (11) to guanidylated ramoplanin antibi-
mM solution of the crude peptide in 20% DMSO/H2O for four daysotic derivative 3 were performed at 25
C using a Microcal MCS
in a 250 ml round bottom flask exposed to air. The crude cyclictitration microcalorimeter equipped with a 250 l injection syringe
peptide was purified to homogeneity by reversed-phase HPLC (con-and a 400 rpm stirring rate. Both ramoplanin derivative 3 and PG
ditions: Phenomenex Jupiter C4 column (5, 300 A˚, 250  21.2analog 11 were dissolved in water and vacuum degassed before
mm); mobile phase A, H2O/heptafluoroisobutyric acid (99.9/0.1, v/v),use. Compound 11 (20  10 l injection of a 5.4 mM solution) was
mobile phase B, ACN/H2O/heptafluoroisobutyric acid (89.9/10/0.1,injected into an ITC cell containing ca. 1.3 ml of 3 (1 mM). Control
v/v/v). Fractions containing pure cyclic peptide were identified byexperiments were performed under identical conditions by injection
MS, combined, and lyophilized to yield pure 16 (52 mg) as a whiteof 3 into water alone (to correct for heat of dilution effects), com-
powder: HR-MS (ESI) m/z: calcd. 1339.58151, actual 1339.5803 (Mpound 11 into water, and the reverse experiment of titrating water
H); 1H NMR (D2O)  0.713 (t, J  7.0 Hz, octanoic acid CH3), 0.967into solutions of 3 or 11. Titration data were processed using the
(d, J  6.5 Hz, Thr8 HC), 0.989-1.113 (m, octanoic acid HC , , ,software package Origin.
, Orn4 HC, Orn4 HC, Thr5 HC), 1.308 (m, Orn4 HC), 1.440 (m,
Orn10 HC), 1.574 (m, Orn4 HC), 1.767 (m, Orn4 HC), 2.011 (m, Orn4,
HC), 2.105 (d, J  5.5 Hz, octanoic acid HC), 2.622 (m, Asn1 HC),[Orn4, Orn10]-Diguanidylated Ramoplanin (3)
A dry nitrogen-flushed 50 ml round bottom flask was charged with 2.776 (m, Orn4 HC), 2.864-2.887 (m, Orn4 HC, Cys9 HC), 2.976 (m,
Cys2 HC), 3.072 (m, Cys9 HC), 3.150 (m, Cys2 HC), 3.909 (m, Thr8Ramoplanin (200 mg, 0.0783 mmol, 1 eq), 1H-pyrazole-1-carboxa-
midine (458 mg, 1.57 mmol, 20 eq) and a teflon stirbar. The flask HC), 4.122 (m, Thr5 HC), 4.221-4.237 (m, Orn10 HC, Thr8 HC),
4.562 (m, Orn4 HC), 4.719-4.764 (m, Asn1 HC), 5.233 (s, Hpg6 HC),was sealed and diisopropylethylamine (372 mg, 1.57 mmol, 20 eq)
in DMF (2 ml) was added by syringe. The solution was allowed to 5.277 (s, Orn10 HC), 5.385 (s, Hpg3 HC), 5,520 (s, Hpg7 HC), 6.737
(d, J 8.5 Hz Hpg6 aromatic c,e), 6.769 (d, J 8.5 Hz, Hpg3 aromaticstir for 8 hr, then azeotropically evaporated with toluene under high
vacuum three times and dried on high vacuum overnight. Excess c,e), 6.799 (d, J  8.5 Hz, Hpg7 aromatic c,e), 7.088 (d, J  8.0 Hz
Hpg6 aromatic b,f), 7.129 (d, J  8.5 Hz, Hpg3 aromatic b,f), 7.182starting material was removed by washing the solid with absolute
ethanol (10 ml) with sonication, followed by filtration. The remaining (d, J  8.5 Hz, Hpg7 aromatic b,f) ppm; 13C NMR (D2O)  16.150,
21.565, 21.796, 24.734, 26.045, 28.000, 30.161, 30.695, 30.853,solid was dissolved in HPLC Buffer A, purified by preparative re-
versed phase HPLC, and lyophilized to afford the title compound as 30.950, 33.718, 38.210, 38.878, 41.415, 41.488, 41.561, 53.131,
55.390, 55.815, 56.264, 56.519, 59.238, 59.809, 60.695, 62.407,a white solid (80.2 mg, 38.7% yield): MALDI TOF-MS calcd. 2638.15,
actual 2639.5 (M  H); preparative HPLC conditions, Vydac C18 62.832, 69.607, 118.450, 118.595, 118.644, 118.862, 129.364,
130.214, 130.566, 131.538, 131.756, 131.890, 132.157, 132.388,column (25 mm 250 mm), mobile phase A H2O/ACN/TFA (80/20/
0.1, v/v), mobile phase B H2O/ACN/TFA (10/90/0.1, v/v); analytical 173.655, 173.934, 174.262, 174.407, 174.588, 174.942, 175.111,
175.281, 175.415, 176.192, 176.823, 178.268, 179.846 ppm.HPLC, Vydac C18 (4.5mm  250mm) Rt: 35.05 min.
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